Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype.
Potential therapeutic targets of triple-negative breast cancer based on its intrinsic subtype.
复制标题
DOI：
10.18632/oncotarget.20274
复制
发表时间：
2017-09-22
期刊：
影响因子：
--
通讯作者：
Deng CX
中科院分区：
文献类型：
--
作者：
Shao F;Sun H;Deng CX
三阴性乳腺癌是人类乳腺癌的一种侵袭性亚型，以雌激素受体(ER)阴性、孕激素受体(PR)阴性、人表皮生长因子受体2(HER2)阴性为特征。TNBC是最难治疗的乳腺癌亚型，因为它对目前的临床靶向治疗无效，复发率高，预后差。因此，迫切需要确定治疗靶点，开发更有效的分层药物来治疗TNBC。在这里，我们根据TNBC的内在亚型，对其潜在的治疗靶点进行综述。我们还综述了在肿瘤细胞的不同亚群中发现的异常激活信号，包括雄激素受体(AR)和PI3K/AKT/mTOR、Notch、Wnt/β-catenin、Hedge-HOG和转化生长因子-β信号通路，这些信号通路在肿瘤的多个发育阶段中发挥着重要作用。对这些信号通路和治疗靶点的仔细分析将对药物开发和临床试验产生重大影响，从而导致对这种致命疾病的有效治疗。
Triple-negative breast cancer (TNBC) is an aggressive subgroup of human breast cancer, which is characterized as estrogen receptor (ER) negative, progesterone receptor (PR) negative, and human epidermal growth factor receptor 2 (HER2) negative. TNBC is the most difficult breast cancer subgroup to treat, due to its unresponsiveness to current clinical targeted therapies, high rate of recurrence, and poor prognosis. Thus, there is an urgent medical need to identify therapeutic targets and develop more effective stratified medicine for the treatment of TNBC. Here we review the potential therapeutic targets for TNBC based on its intrinsic subtype. We also review the aberrant activated signals found in different subgroups of TNBC, including androgen receptor (AR) and PI3K/AKT/mTOR, Notch, Wnt/β-catenin, Hedge-hog, and TGF-β signaling pathways, which play essential roles in multiple development stages of TNBC. The careful analysis of these signaling pathways and therapeutic targets would have significant impact on the drug development and clinical trials, leading to effective therapies for this deadly disease.